

1614

AMENDMENT TRANSMITTAL LETTER (Large Entity)

Applicant(s): A. Mangel et al.

Docket No.

PU3375USW

Serial No.

09/529,050

Filing Date

April 5, 2000

Examiner

P. Spivack

Group Art Unit

1614

Invention:

MEDICAMENTS FOR THE TREATMENT OF NON-CONSTIPATED FEMALE IRRITABLE BOWEL SYNDROME

(As Amended)

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

RECEIVED


NOV 02 2000

TECH CENTER 1604/2000

CLAIMS AS AMENDED

|  | CLAIMS REMAINING<br>AFTER AMENDMENT | HIGHEST #<br>PREV. PAID FOR | NUMBER EXTRA<br>CLAIMS PRESENT | RATE    | ADDITIONAL<br>FEE |
|--|-------------------------------------|-----------------------------|--------------------------------|---------|-------------------|
| TOTAL CLAIMS   | 21 -                                | 20 =                        | 1 x                            | \$18.00 | \$18.00           |
| INDEP. CLAIMS  | 6 -                                 | 3 =                         | 3 x                            | \$80.00 | \$240.00          |
| Multiple Dependent Claims (check if applicable) <input type="checkbox"/> |                                     |                             |                                |         | \$0.00            |
| TOTAL ADDITIONAL FEE FOR THIS AMENDMENT                                  |                                     |                             |                                |         | \$258.00          |


- ☐ No additional fee is required for amendment.
- ☒ Please charge Deposit Account No. 07-1392 in the amount of \$258.00  
A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 07-1392.  
A duplicate copy of this sheet is enclosed.
- ☒ Any additional filing fees required under 37 C.F.R. 1.16.
- ☒ Any patent application processing fees under 37 CFR 1.17.

  
Signature

Dated: 10/26/00

Lorie Ann Morgan, Reg. No. 38,181  
Attorney for Applicants  
Glaxo Wellcome, Inc.  
Five Moore Drive, PO Box 13398  
Research Triangle Park  
North Carolina 27709-3398  
Telephone: (919) 483-8222

I certify that this document and fee is being deposited on 10-26-00 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.



Signature of Person Mailing Correspondence

Allyson K. Jacobs

Typed or Printed Name of Person Mailing Correspondence

CC: